INS and lung carcinoma: Exposure either to metformin or to insulin was associated with a lower risk of lung cancer-specific mortality, and this approached statistical significance (HR 0.82, 95% CI 0.72–92 for metformin and HR 0.65, 95% CI 0.44–95 for insulin, Table 2).